Browse studies

Find your next paid study

75 recruiting studies matching your filters

A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants With COPD

This is a Phase 2 study of the efficacy, safety, tolerability and pharmacokinetics of two doses of EXPD-101 in participants with COPD. Study participants will …

Chronic Obstructive Pulmonary Disease (COPD)

Estimated

~$10 – $8,750

Expedition Therapeutics, IncNCT07684820

Observational

Evaluation of the Paramedic Evaluation for Acute COPD Exacerbation (PEACE) Intervention

Chronic Obstructive Pulmonary Disease (COPD) is a serious lung condition that affects millions of people in the United States. Each year, it leads to about 150…

COPD (Chronic Obstructive Pulmonary Disease)

Estimated

~$10 – $6,250

University of Massachusetts, WorcesterNCT07072039

Phase 3

A Randomized, Double-blind, Parallel Group, Multi-center, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease (THARROS)

This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with…

COPD (Chronic Obstructive Pulmonary Disease)

Estimated

~$10 – $7,500

AstraZenecaNCT06283966

Observational

An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema: The CONVERT II Trial

This is a prospective, open-label, multi-center, single-arm study planned to enroll 200 subjects with heterogeneous emphysema and collateral ventilation (CV) i…

Emphysema, PulmonaryEmphysema or COPD

Estimated

~$10 – $8,750

Pulmonx CorporationNCT06035120

Phase 2

A Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of WIN378 in Participants With Moderate - Severe Chronic Obstructive Pulmonary Disease

This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate - severe chronic obstructive pulmonary disease…

COPD (Chronic Obstructive Pulmonary Disease)

Estimated

~$10 – $7,500

Windward BioNCT07646587

Phase 4

Nebulizer Versus Handheld Maintenance Therapy for Patients With COPD

Multi-site, randomized controlled trial to determine whether patients who report NO symptomatic benefit with their maintenance hand-held inhaler(s), benefit up…

COPD (Chronic Obstructive Pulmonary Disease)Chronic Obstructive Pulmonary Disease (COPD)

Estimated

~$10 – $6,250

COPD FoundationNCT07816835

Phase 2

A Multicentre, Parallel-group, Phase IIb, Randomised, Double-blind, Placebo-controlled, 3-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO)

This Phase IIb dose-ranging study will evaluate the efficacy and safety of 2 different doses of AZD6793 compared with placebo tablets in participants with mode…

Chronic Obstructive Pulmonary Disease (COPD)

Estimated

~$10 – $7,500

AstraZenecaNCT07082738

Phase 2

Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD (COPD-OMA)

This research is being done to test if a drug called omalizumab can help people with Chronic Obstructive Pulmonary Disease (COPD) and allergies. Each particip…

Chronic Obstructive Pulmonary Disease (COPD)Allergies

Estimated

~$10 – $6,250

Johns Hopkins UniversityNCT07059091

Phase 3

A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Mo…

Chronic Obstructive Pulmonary Disease (COPD)

Estimated

~$10 – $7,500

AstraZenecaNCT06883305

Phase 3

A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Mo…

Chronic Obstructive Pulmonary Disease (COPD)

Estimated

~$10 – $7,500

AstraZenecaNCT06878261

A Multicenter Study of the Impact of a COPD Identification and Referral System on Patient Follow Up and Outcomes After an Acute COPD Exacerbation Resulting in an Emergency Department Visit or Hospitalization

The goal of this study is to evaluate the impact of implementing an AI-enabled clinical workflow tool (Viz COPD) on respiratory specialist follow up and clinic…

COPD (Chronic Obstructive Pulmonary Disease)

Estimated

~$10 – $1,050

Viz.ai, Inc.NCT07118306

The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry

The STRIDE Registry will evaluate the real-world effectiveness and safety of dupilumab in participants with COPD. The primary objective is to describe characte…

COPD (Chronic Obstructive Pulmonary Disease)

Estimated

~$10 – $1,125

SanofiNCT07612878